WEST PHARMACEUTICAL SERVICES, INC. Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent
WEST PHARMACEUTICAL SERVICES, INC. (WST) reported Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent of $400.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent · last filed 2026-07-23
- WEST PHARMACEUTICAL SERVICES, INC. other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for the quarter ending 2026-06-30 was $400.00K.
- WEST PHARMACEUTICAL SERVICES, INC. other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for the quarter ending 2026-03-31 was $100.00K.
- WEST PHARMACEUTICAL SERVICES, INC. other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for the quarter ending 2025-12-31 was $1.40M, a 68.18% decline year-over-year.
- WEST PHARMACEUTICAL SERVICES, INC. other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for the quarter ending 2025-09-30 was $700.00K.
- WEST PHARMACEUTICAL SERVICES, INC. other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- WEST PHARMACEUTICAL SERVICES, INC. other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for fiscal 2024 was $3.60M, a 260.00% increase from fiscal 2023.
- WEST PHARMACEUTICAL SERVICES, INC. other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for fiscal 2023 was $1.00M, a 54.55% decline from fiscal 2022.
- WEST PHARMACEUTICAL SERVICES, INC. other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for fiscal 2022 was $2.20M, a 8.33% decline from fiscal 2021.
| Period end | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | $400.00K 10-Q · filed 2026-07-23 | $500.00K 10-Q · filed 2026-07-23 | $1.90M derived: sum of 3 quarters · filed 2026-07-23 | $2.60M derived: sum of 4 quarters · filed 2026-07-23 |
| 2026-03-31 | $100.00K 10-Q · filed 2026-04-23 | $1.50M derived: sum of 2 quarters · filed 2026-04-23 | $2.20M derived: sum of 3 quarters · filed 2026-04-23 | $1.20M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $2.10M derived: sum of 2 quarters · filed 2026-02-17 | $1.10M derived: sum of 3 quarters · filed 2026-07-23 | $0.00 10-K · filed 2026-02-17 |
| 2025-09-30 | $700.00K 10-Q · filed 2025-10-23 | -$300.00K derived: sum of 2 quarters · filed 2026-07-23 | -$1.40M 10-Q · filed 2025-10-23 | $3.00M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-06-30 | -$1.00M 10-Q · filed 2026-07-23 | -$2.10M 10-Q · filed 2026-07-23 | $2.30M derived: sum of 3 quarters · filed 2026-07-23 | -$200.00K derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-03-31 | -$1.10M 10-Q · filed 2026-04-23 | $3.30M derived: sum of 2 quarters · filed 2026-04-23 | $800.00K derived: sum of 3 quarters · filed 2026-04-23 | $1.50M derived: sum of 4 quarters · filed 2026-04-23 |
| 2024-12-31 | $4.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $1.90M derived: sum of 2 quarters · filed 2026-02-17 | $2.60M derived: sum of 3 quarters · filed 2026-02-17 | $3.60M 10-K · filed 2026-02-17 |
| 2024-09-30 | -$2.50M 10-Q · filed 2025-10-23 | -$1.80M derived: sum of 2 quarters · filed 2025-10-23 | -$800.00K 10-Q · filed 2025-10-23 | -$1.70M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $700.00K 10-Q · filed 2025-07-24 | $1.70M 10-Q · filed 2025-07-24 | $800.00K derived: sum of 3 quarters · filed 2026-02-17 | $1.20M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $1.00M 10-Q · filed 2025-04-24 | $100.00K derived: sum of 2 quarters · filed 2026-02-17 | $500.00K derived: sum of 3 quarters · filed 2026-02-17 | $1.80M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | -$900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | -$500.00K derived: sum of 2 quarters · filed 2026-02-17 | $800.00K derived: sum of 3 quarters · filed 2026-02-17 | $1.00M 10-K · filed 2026-02-17 |
| 2023-09-30 | $400.00K 10-Q · filed 2024-10-24 | $1.70M derived: sum of 2 quarters · filed 2024-10-24 | $1.90M 10-Q · filed 2024-10-24 | $300.00K derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | $1.30M 10-Q · filed 2024-07-25 | $1.50M 10-Q · filed 2024-07-25 | -$100.00K derived: sum of 3 quarters · filed 2025-02-18 | $1.00M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | $200.00K 10-Q · filed 2024-04-25 | -$1.40M derived: sum of 2 quarters · filed 2025-02-18 | -$300.00K derived: sum of 3 quarters · filed 2025-02-18 | $1.40M derived: sum of 4 quarters · filed 2025-02-18 |
| 2022-12-31 | -$1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | -$500.00K derived: sum of 2 quarters · filed 2025-02-18 | $1.20M derived: sum of 3 quarters · filed 2025-02-18 | $2.20M 10-K · filed 2025-02-18 |
| 2022-09-30 | $1.10M 10-Q · filed 2023-10-26 | $2.80M derived: sum of 2 quarters · filed 2023-10-26 | $3.80M 10-Q · filed 2023-10-26 | $4.40M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $1.70M 10-Q · filed 2023-07-27 | $2.70M 10-Q · filed 2023-07-27 | $3.30M derived: sum of 3 quarters · filed 2024-02-20 | $3.40M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $1.00M 10-Q · filed 2023-04-27 | $1.60M derived: sum of 2 quarters · filed 2024-02-20 | $1.70M derived: sum of 3 quarters · filed 2024-02-20 | $2.00M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $700.00K derived: sum of 2 quarters · filed 2024-02-20 | $1.00M derived: sum of 3 quarters · filed 2024-02-20 | $2.40M 10-K · filed 2024-02-20 |
| 2021-09-30 | $100.00K 10-Q · filed 2022-10-27 | $400.00K derived: sum of 2 quarters · filed 2022-10-27 | $1.80M 10-Q · filed 2022-10-27 | |
| 2021-06-30 | $300.00K 10-Q · filed 2022-07-28 | $1.70M 10-Q · filed 2022-07-28 | ||
| 2020-12-31 | -$1.00M 10-K · filed 2023-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |